Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 1, 2012, Pages

  Giordano, Arturo ^a   Romano, Simona ^b   Monaco, Mario ^c   Sorrentino, Antonio ^b   Corcione, Nicola ^a   di Pace, Anna Laura ^b   Ferraro, Paolo ^a   Nappo, Giovanna ^b   Polimeno, Michele ^a   Romano, Maria Fiammetta ^b  

^a Fondazione Toscana G Monasterio   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Pineta Grande Hospital   (Italy)

Author keywords

Cyclins; Endoglin; Signal transduction

Indexed keywords

ATORVASTATIN; BETA CATENIN; BROXURIDINE; CYCLIN B; DNA; ENDOGLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TACROLIMUS;

AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESTENOSIS; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; THROMBOSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84255182396     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00490.2011     Document Type: Article

References (34)

1. Abraham RT, Wiederrecht GJ. Immunopharmacology of Rapamycin. Annu Rev Immunol 14: 483-510, 1996.
2. Albiñana V, Sanz-Rodríguez F, Recio-Poveda L, Bernabéu C, Botella LM. Immunosuppressor FK506 increases endoglin and activin receptorlike kinase 1 expression and modulates transforming growth factor-p1 signaling in endothelial cells. Mol Pharmacol 79: 833-843, 2011.
3. Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, Tremoli E, Bonomini S, Simon A, Closs EI, Dall'Asta V, Bussolati O. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 78: 563-571, 2008.
4. Crabtree GR. Calcium, calcineurin, and the control of transcription. J Biol Chem 276: 2313-2316, 2001.
5. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptorlike kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961, 2007.
6. Davis C, Fischer J, Ley K, Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost 1: 1699-1709, 2003.
7. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33: 1569-1582, 1992.
8. Giordano A, Romano A. Inhibition of human in-stent restenosis: a molecular view. Curr Opin Pharmacol 11: 372-377, 2011.
9. Giordano A, Romano S, Mallardo M, D'Angelillo A, Cali G, Corcione N, Ferraro P, Romano MF. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res 79: 519-526, 2008.
10. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJ, Bühring HJ, Bernabeu C, van Mourik JA, Letarte M. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4: 83-92, 1992.
11. Hamada N, Miyata M, Eto H, Shirasawa T, Akasaki Y, Nagaki A, Chuwa T. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. Atherosclerosis 208: 97-103, 2010.
12. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 36, Suppl 2S: 25S-32S, 2004.
13. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47: 648-657, 2000.
14. Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones MA. preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 35: 717-721, 2009.
15. Laufs U, Marra D, Node K, Liao JK. 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27kip1. J Biol Chem 274: 21926-21931, 1999.
16. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduc-tion. EMBO J 23: 4018-4028, 2004.
17. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5: 2236-2243, 2005.
18. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases regulating the immune response. Nat Rev Immunol 7: 202-212, 2007.
19. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grünenfelder J, Zünd G, Tanner F, Lüscher TF. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48: 286-292, 2006.
20. Morice MC, Bestehorn HP, Carrie D, Macaya C, Aengevaeren W, Wijns W, Dubois C, De Winter R, Verheye S, Hoffmann S, Pachinger O, Di Mario C. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2: 45-52, 2006.
21. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11: 62-72, 2004.
22. Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, Pospechova K, Semecky V. Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice. J Atheroscler Thromb 16: 265-274, 2009.
23. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96: 7797-7802, 1999.
24. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235, 2005.
25. Rinker A, Nusser T, Grossmann G, Koenig W, Wöhrle J. Angio-graphic results of a Tacrolimus-eluting stent in acute coronary syndrome lesions. Clin Res Cardiol 98: 89-93, 2009.
26. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun CC, Dacis BR, Braunwald E. The effect of pravastatin on coronary events after myo-cardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators (Abstract). N Engl J Med 335: 1001, 1996.
27. Sewell TJ, Lam E, Martin MM, Leszyk J, Weidner J, Calaycay J, Griffin P, Williams H, Hung S, Cryan J, Sigal NH, Wiederrecht GJ. Inhibition of calcineurin by a novel FK-506-binding protein. J Biol Chem 269: 21094-21102, 1994.
28. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC. Rapamycin, but not FK-506, increases endo-thelial tissue factor expression: implications for drug-eluting stent design. Circulation 112: 2002-2011, 2005.
29. Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, Scardaci F, Ussia G, Galassi AR, Fiscella D, Meheran R, Dangas G. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry. Catheter Cardiovasc Interv 73: 243-248, 2009.
30. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869, 2007. Review.
31. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89, 2008.
32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339: 1349-1357, 1998.
33. van Laake LW, van den Driesche S, Post S, Feijen A, Jansen MA, Driessens MH, Mager JJ, Snijder RJ, Westermann CJJ, Doevendans PA, van Echteld CJA, ten Dijke P, Arthur HM, Goumans MJ, Lebrin F, Mummery CL. Endoglin has a crucial role in blood cell-mediated vascular repair. Circulation 114: 2288-2297, 2006.
34. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res 90: 340-347, 2002.